STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Severe Eosinophilic Asthma Clinical Trial

— STEP  

Official title:

STEP: A Prospective, Interventional, Multicenter, Single-Arm Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06465485
• Other study ID #: D3250L00046
• Status: Recruiting
• Phase: Phase 3
• Start date: February 28, 2024
• Est. completion date: July 31, 2026

Study information

• Verified date: June 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to maintain asthma control in Chinese patients.

Description:

The study population will be approximately 200 patients on MD/HD ICS/LABA with and without LTRA or LAMA or theophylline and meeting study inclusion and exclusion criteria in China. After patients sign the informed consent, they will undergo a screening visit (Visit 1, Week -1 to Week 0) to assess eligibility criteria. Patients who meet eligibility criteria and complete study baseline assessments will enter the study and receive the first dose of benralizumab at visit 2 (Week 0).

The benralizumab treatment includes 4 phases: Induction Phase (16 weeks), Reduction Phase (24 weeks), Maintenance Phase (16 weeks) and Follow-up Phase (4 weeks). After initiation of benralizumab 30 mg administered subcutaneously every 4 weeks (Q4W) for the first 3 doses (Visits 2 to 4), then every 8 weeks (Q8W) thereafter.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 31, 2026
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 100 Years

Eligibility

Inclusion Criteria:

Informed Consent:

1. Provision of informed consent prior to any study-specific procedures. Written informed consent, and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable local guidelines.

Age:

2. Patient must be aged 12 years old or above, inclusively, at the time of Visit 1(Week -1 to Week 0) For those patients, who are 17 on the day of Visit 1(Week -1 to Week 0) but will turn 18 after this day, will be considered an adolescent for the purposes of this study.

Type of Patient and Disease Characeristics

3. Documented diagnosis of severe eosinophilic asthma (EOS=150 cells/µL at enrollment, and if EOS 150-<300 cells/µL at enrollment, must have EOS=300 cells/µL at sometime within 1 year before enrollment)

4. Documented current maintenance treatment with MD/HD ICS + LABA with up to one additional controller

• Other acceptable asthma controller includes LTRA, LAMA or theophylline

5. On stable MD/HD ICS(>250µg fluticasone propionate dry powder formulation equivalents total daily dose) + LABA for =2 months prior to enrollment (see Appendix F for medium and high daily ICS doses by formulation)

6. On stable LTRA or LAMA or theophylline (=2 weeks) is allowed

7. Documented at least one exacerbation in the year prior to enrolment

• A qualifying historical asthma exacerbation is a symptomatic worsening requiring systemic corticosteroid (i.e., oral, intravenous (IV) or intramuscular; any healthcare setting or temporary increase from a stable maintenance dose of oral corticosteroid) or that resulted in hospitalization or emergency room/urgent care visit.

Source documentation is required for physician-diagnosed asthma, ICS-LABA use and asthma exacerbations over the prior year. A patient verbal history suggestive of asthma symptoms and/or prior asthma exacerbations, but without supporting documentation, is not sufficient to satisfy these inclusion criteria.

Examples of acceptable documentation of the asthma disease state and prior asthma exacerbations include clinic visit (primary or specialist Health care provider (HCP)), emergency room/urgent care, or hospital records listing asthma as a current problem, plus documentation of at least 1 asthma exacerbations during the 12 months prior to ICF.

Weight:

8. Weight of =40 kg.

Sex and Contraceptive/Barrier Requirements:

9. Male and/or female Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Female patients:

• Females not of childbearing potential are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Females will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to Visit 1(Week -1 to Week 0) without an alternative medical cause. The following age-specific requirements apply:

• Females < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range.

• Females = 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.

• Female patients of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Females of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 12 weeks after last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician.

• The following are not acceptable methods of contraception: periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea. Female condom and male condom should not be used together.

• All WOCBP must have a negative serum pregnancy test result at Visit 1(Week -1 to Week 0).

• Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the patient (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) [(periodic abstinence eg, calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods of contraception], a vasectomised partner, Implanon®, bilateral tubal occlusion, intrauterine device/levonorgestrel intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™, Xulane™, or NuvaRing®.

Exclusion Criteria-

Medical Conditions:

1. Unable to commit to the scheduled visits as required by the protocol, or unable to commit to undergoing protocol guided reductions in asthma therapy, as directed by the Investigator.

2. Clinically important pulmonary disease other than asthma (e.g., active lung infection, chronic obstructive pulmonary disease [COPD], bronchiectasis, pulmonary fibrosis, cystic fibrosis), or ever been diagnosed with pulmonary or systemic disease, other than asthma, that is associated with elevated peripheral eosinophil counts (e.g., allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

3. Current smokers or former smokers with a smoking history =20 pack/years.

4. History of alcohol or drug abuse within 12 months prior to Visit 1(Week -1 to Week 0).

5. A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1(Week -1 to Week 0) that has not been treated with, or has failed to respond to, standard of care therapy.

6. History of anaphylaxis to any biologic therapy.

7. Known history of allergy or reaction to any component of the study treatment formulation.

8. Respiratory exacerbation requiring use of Systemic corticosteroids (SCS) or acute upper/lower respiratory infection that required antibiotics or antiviral medication within 30 days prior to Visit 1(Week -1 to Week 0). An extension of the screening period up to 3 months is allowed to ensure that a patient recovering from any repiratory exacerbation or acute upper/lower respiratory infection can be included.

9. A history of known immunodeficiency disorder, including human immunodeficiency virus.

10. Current or history of malignancy within 5 years before the screening visit with the following exceptions:

• In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to screening.

• Basal cell or superficial squamous skin cancer. Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.

11. Exclusion for any of the following:

• Previous allogeneic bone marrow transplant.

• Non-leucocyte depleted whole blood transfusion within 120 days of genetic sample collection.

12. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

1. Affect the safety of the patient throughout the study,

2. Confound the study results or impact the scientific validity of the data outcome, or

3. Impede the patient's ability to complete the entire duration of study.

Prior/Concomitant Therapy:

13. Oral corticosteroid use during 4 weeks prior to Visit 1(Week -1 to Week 0).

14. Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months or 5 halflives (whichever is longer) prior to the date informed consent is obtained.

15. Receipt of any marketed or investigational biologic agent within 4 months or 5 half lives (whichever is longer) prior to Visit 1(Week -1 to Week 0) or receipt of any investigational non biologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1(Week -1 to Week 0). Exception:

1. For marketed non-respiratory biologics, it is allowed if the patient is stable on treatment for at least 3 months prior to Visit 1(Week -1 to Week 0) and throughout the study.

2. Covid-related prevention and treatment

16. Receipt of live attenuated vaccines 30 days prior to the date of first dose of benralizumab.

17. Intention to use any concomitant medication that is not permitted or failure to complete the required washout period for a particular prohibited medication.

18. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.

19. Received bronchial thermoplasty (BT) as treatment of asthma within 12 months prior to Visit 1.

Prior/Concurrent Clinical Study Experience:

20. Concurrent participation in another clinical study with an Investigational Product or a post-authorization safety study

Diagnostic Assessments:

21. Any clinically significant abnormal findings in physical examination, medical history, vital signs, haematology, or clinical chemistry during the enrolment period, which in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.

Other Exclusions:

22. For females only - currently pregnant (confirmed with positive pregnancy test), breast feeding, or lactating.

23. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

24. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

25. Previous enrolment in the present study.

Related Conditions & MeSH terms

• Asthma
• Pulmonary Eosinophilia
• Severe Eosinophilic Asthma

Intervention

Drug:
• Benralizumab
Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs or theophylline will be enrolled into this single arm treatment.

Locations

Country	Name	City	State
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Chengdu
China	Research Site	Chengdu
China	Research Site	Guangzhou
China	Research Site	Guangzhou
China	Research Site	Hangzhou
China	Research Site	Hohhot
China	Research Site	Huzhou
China	Research Site	Jinan
China	Research Site	Jinan
China	Research Site	Lanzhou
China	Research Site	Lanzhou
China	Research Site	Nanjing
China	Research Site	Nanning
China	Research Site	Ningbo
China	Research Site	Shanghai
China	Research Site	Shanghai
China	Research Site	Shenzhen
China	Research Site	Shenzhen
China	Research Site	Shenzhen
China	Research Site	Shenzhen
China	Research Site	Shijiazhuang
China	Research Site	Shijiazhuang
China	Research Site	Suzhou
China	Research Site	Suzhou
China	Research Site	Taiyuan
China	Research Site	Tangshan
China	Research Site	Wenzhou
China	Research Site	Wuhu
China	Research Site	Xi'an
China	Research Site	Xinxiang
China	Research Site	Yangzhou
China	Research Site	Zhangzhou
China	Research Site	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen	Main outcomes: Proportion of patients with at least one controller medication category reduction at end of reduction phase; discontinuation of LTRA, or; discontinuation of LAMA, or; discontinuation of theophylline, or; getting to MD ICS/LABA, or; getting to LD ICS/LABA; Supportive outcomes: Proportion of patients with individual category reduction at end of reduction phase; Proportion of patients with =2 category reductions in controller medication; In sub-group of patients who meet reduction criteria; proportion of patients with at least one controller medication category reduction,; proportion of patients with individual category reduction; proportion of patients with =2 reductions in controller medication at end of reduction phase	within 40 weeks after the first administration
Secondary	To assess standard asthma efficacy measures for benralizumab treated patients when reducing their standard of care asthma controller regimen for pulmonary function measured by pre-BD FEV1 in litres	Change in pre-BD FEV1 measured in litres from beginning of reduction phase to end of reduction phase	From 16~40 weeks
Secondary	To assess standard asthma efficacy measures for benralizumab treated patients when reducing their standard of care asthma controller regimen for asthma symptoms control measured by ACQ-IA Score	Change in measured by ACQ-IA score from beginning of reduction phase to end of reduction phase; Measured by Proportion of patients with no deterioration (defined as ACQ-IA score change <0.5 score since last visit) during reduction phase	From 16~40 weeks
Secondary	To assess if reductions in background therapies achieved at end of reduction phase are maintained until end of maintenance phase	Measured by Proportion of patients at the end of the maintenance phase who use the same background therapy that they achieved at the end of the reduction phase	from 40-56 weeks
Secondary	To assess if reductions in background therapies achieved at end of reduction phase are maintained until end of maintenance phase	Change in measured by ACQ-IA score from the end of the reduction phase to the end of the maintenance phase	from 40-56 weeks
Secondary	To assess if reductions in background therapies achieved at end of reduction phase are maintained until end of maintenance phase	Change in measured by FEV1 in litres from the end of the reduction phase to the end of the maintenance phase	from 40-56 weeks
Secondary	To assess standard asthma efficacy measures for benralizumab treated patients at induction phase	Change in measured by FEV1 in litres from beginning of induction phase to end of induction phase	within 0-16 weeks after first administration
Secondary	To assess standard asthma efficacy measures for benralizumab treated patients at induction phase	Change in measured by ACQ-IA score from beginning of induction phase to end of induction phase; Measured by Proportion of patients achieving ACQ-IA score MCID improvement (defined as change in ACQ-IA score =-0.5 compared to beginning of induction phase) at end of induction phase	within 0-16 weeks after first administration
Secondary	To assess overall asthma exacerbation rate during the study of severe eosinophilic asthma patients treated with benralizumab	Annualized asthma exacerbation rate during the study (from first dose to EOT) and 1-year baseline period; Change in annualized asthma exacerbation rate during study phase vs. 1-year baseline period; Annualized asthma exacerbation rate Defined as Number of exacerbations×365.25/(Follow-Up Date-First Benralizumab dose date+1)	within 56 weeks after first administration
Secondary	To assess biomarkers of severe eosinophilic asthma patients treated with benralizumab	Baseline and follow-up visits, and change from baseline: Blood EOS measured as cells per litre	from -1 week to 56 week
Secondary	To assess biomarkers of severe eosinophilic asthma patients treated with benralizumab	Baseline and follow-up visits, and change from baseline:· FeNO measured as parts per billion	from -1 week to 56 week
Secondary	To assess the safety and tolerability of benralizumab.Number of participants with treatment-related adverse events as asessed by CTCAEV5.0.	The number of patients experiencing any Treatment related AEs/SAEs	from -1 week to 60 week